The forgotten members of the glucagon family

Diabetes Research and Clinical Practice

Volumn 106, Issue 1, 2014, Pages 1-10

  Bataille, Dominique ^a   Dalle, Stéphane ^b  

^a INSERM   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

Glicentin; Glucagon; Miniglucagon; Oxyntomodulin; Post translational processing; Proglucagon

Indexed keywords

GLICENTIN; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; MINIGLUCAGON; OXYNTOMODULIN; UNCLASSIFIED DRUG; GLUCAGON (19-29); PEPTIDE FRAGMENT;

DRUG EFFECT; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCAGON RELEASE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INTESTINAL SECRETION; NONHUMAN; OBESITY; PANCREAS ISLET; REVIEW; STOMACH ACID SECRETION; ANIMAL; ENERGY METABOLISM; MULTIGENE FAMILY; PHYSIOLOGY;

ANIMALS; ENERGY METABOLISM; GLICENTIN; GLUCAGON; HUMANS; MULTIGENE FAMILY; OXYNTOMODULIN; PEPTIDE FRAGMENTS;

EID: 84908027758     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.06.010     Document Type: Review

References (66)

1. Glucagon I. Handbook experimental pharmacology 1983, 66:535. I.
2. Glucagon II. Handbook experimental pharmacology 1983, 66:700. II.
3. Glucagon III. Handbook experimental pharmacology 1996, 123:349 p.
4. Cho Y.M., Fujita Y., Kieffer T.J. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol 2013, 28:262-274.
5. Bataille D., Coudray A.M., Carlqvist M., Rosselin G., Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Isolation of the peptide. FEBS Lett 1982, 146:73-78.
6. Bataille D., Tatemoto K., Gespach C., Jörnvall H., Rosselin G., Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterisation of the peptide. FEBS Lett 1982, 146:79-86.
7. Dubrasquet M., Bataille D., Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rat. Biosci Rep 1982, 2:391-395.
8. Carles-Bonnet C., Jarrousse C., Niel H., Martinez J., Bataille D. Oxyntomodulin and its (19-37) and (30-37) fragments inhibit histamine-stimulated gastric acid secretion in the conscious rat. Eur J Pharmacol 1991, 203:245-252.
9. Jarrousse C., Carles-Bonnet C., Niel H., Sabatier R., Audousset-Puech M.-P., Blache P., et al. Inhibition of gastric acid secretion by oxyntomodulin and its (19-37) fragment in the conscious rat. Am J Physiol 1993, 264:G816-G823. (Gastrointest. Liver Physiol. 27).
10. Jarrousse C., Audousset-Puech M.-P., Dubrasquet M., Niel H., Martinez J., Bataille D. Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric secretion. FEBS Lett 1985, 188:81-84.
11. Veyrac M., Ribard D., Daures J.P., Mion H., Le Quellec A., Martinez J., et al. Inhibitory effect of the C-terminal octapeptide of oxyntomodulin on pentagastrin-stimulated gastric acid secretion in man. Scand J Gastroenterol 1989, 24:1238-1242.
12. Carles-Bonnet C., Martinez J., Jarrousse C., Aumelas A., Niel H., Bataille D. H-Lys-Arg-Asn-Lys-Asn-Asn-OH is the minimal active structure of oxyntomodulin. Peptides 1996, 17:557-561.
13. Beauclair F., Eto B., Pansu D., Rodier G., Mochuzoki T., Martinez J., et al. Oxyntomodulin regulates hydromineral transport across the rat small intestine. Dig Dis Sci 1998, 43:1814-1823.
14. Rodier G., Magous R., Mochizuki T., Le Nguyen D., Martinez J., Bali J.P., et al. Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes. Endocrinology 1999, 140:22-28.
15. Pellissier S., Sasaki K., Le-Nguyen D., Bataille D., Jarrousse C. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol Motil 2004, 16:455-463.
16. Ayachi S.E., Borie F., Magous R., Sasaki K., le Nguyen D., Bali J.P., et al. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol. Motil 2005, 17:302-309.
17. Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, 142:4244-4250.
18. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004, 145:2687-2695.
19. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003, 88:4696-4701.
20. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., Wren A.M., Frost G.S., Meeran K., Ghatei M.A., Bloom S.R. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395.
21. Wynne K., Park A.J., Small C.J., Meeran K., Ghatei M.A., Frost G.S., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006, 30:1729-1736.
22. Druce M., Bloom S.R. The regulation of appetite. Arch Dis Child 2006, 91:183-187. (Review).
23. Yu J.H., Kim M.S. Molecular mechanisms of appetite regulation. Diabetes Metab J 2012, 36:391-398.
24. Suzuki K., Jayasena C.N., Bloom S.R. Obesity and appetite control. Exp Diabetes Res 2012, 2012:824305.
25. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
26. Kosinski J.R., Hubert J., Carrington P.E., Chicchi G.G., Mu J., Miller C., et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity 2012, 20:1566-1571.
27. Orci L., Unger R.H. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet 1975, 2:1243-1244.
28. Orci L., Malaisse-Lagae F., Amherdt M., Ravazzola M., Weisswange A., Dobbs R., et al. Cell contacts in human islets of Langerhans. J Clin Endocrinol Metab 1975, 41:841-844.
29. Bosco D., Armanet M., Morel P., Niclauss N., Sgroi A. Unique arrangement of α- and β-cells in human islets of Langerhans. Diabetes 2010, 59:1202-1210.
30. Lefebvre P.J. Diabetes as a paracrinopathy of the islets of Langerhans. Eur Endocrinol 2011, 7:79-83.
31. Lefebvre P.J., Luyckx A.S. Glucose and insulin in the regulation of glucagon release from the isolated perfused dog stomach. Endocrinology 1978, 103:1579-1582.
32. Kawai K., Yokota C., Ohashi S., Watanabe Y., Yamashita K. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 1995, 38:274-276.
33. Marie J.C., Boissard C., Skoglund G., Rosselin G., Breant B. Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma. Endocrinology 1996, 137:4108-4814.
34. Huypens P., Ling Z., Pipeleers D., Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000, 43:1012-1019.
35. Prasadan K., Daume E., Preuett B., Spilde T., Bhatia A., Kobayashi H., Hembree M., Manna P., Gittes G.K. Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. Diabetes 2002, 51:3229-3236.
36. Vuguin P.M., Kedees M.H., Cui L., Guz Y., Gelling R.W., Nejathaim M., Charron M.J., Teitelman G. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 2006, 147:3995-4006.
37. Pictet R.L., Clark W.R., Williams R.H., Rutter W.J. An ultrastructural analysis of the developing embryonic pancreas. Dev Biol 1972, 29:436-467.
38. Trimble E.R., Halban P.A., Wollheim C.B., Renold A.E. Functional differences between rat islets of ventral and dorsal pancreatic origin. J Clin Invest 1982, 69:405-413.
39. Pipeleers D.G., Schuit F.C., in't Veld P.A., Maes E., Hooghe-Peters E.L., Van de Winkel M., et al. Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology 1985, 117:824-833.
40. Pipeleers D.G., in't Veld P.A., Van de Winkel M., Maes E., Schuit F.C., Gepts W. A new in vitro model for the study of pancreatic A and B cells. Endocrinology 1985, 117:806-816.
41. Flamez D., Van Breusegem A., Scrocchi L.A., Quartier E., Pipeleers D., Drucker D.J., et al. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 1998, 47:646-652.
42. Dalle S., Longuet C., Costes S., Broca C., Faruque O., Fontés G., et al. Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line and isolated islets of Langerhans. J Biol Chem 2004, 279:20345-20355.
43. Longuet C., Broca C., Costes S., Hani E.H., Bataille D., Dalle S. Extracellularly regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans. Endocrinology 2005, 146:643-654.
44. Rondas D., Tomas A., Halban P.A. Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. Diabetes 2011, 60:1146-1157.
45. Rondas D., Tomas A., Soto-Ribeiro M., Wehrle-Haller B., Halban P.A. Novel mechanistic link between focal adhesion remodeling and glucose-stimulated insulin secretion. J Biol Chem 2012, 287:2423-2436.
46. Tomas A., Yermen B., Min L., Pessin J.E., Halban P.A. Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway. J Cell Sci 2006, 119:2156-2167.
47. Samols D.R. Glucagon and insulin secretion. Glucagon I handbook of experimental pharmacology 1983, 485-518. Springer, Berlin Heidelberg, New York. P.J. Lefèbvre (Ed.).
48. Moens K., Berger V., Ahn J.M., Van Schravendijk C., Hruby V.J., Pipeleers D., Schuit F. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 2002, 51:669-675.
49. Chrétien M., Gasper L., Benjannet S., Mbikay M., Lazure C., Seidah N.G. The Jeremiah Metzger lecture. From POMC to functional diversity of neural peptides: the key importance of convertases. Trans Am Clin Climatol Assoc 1990, 102:195-224. (Review).
50. Seidah N.G., Day R., Marcinkiewicz, Chrétien M. Precursor convertases: an evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann NY Acad Sci 1998, 839:9-24.
51. Steiner D.F. The proprotein convertases. Curr Opin Chem Biol 1998, 2:31-39.
52. Chesneau V., Pierotti A.R., Prat A., Gaudoux F., Foulon T., Cohen P. N-arginine dibasic convertase (NRD convertase): a newcomer to the family of processing endopeptidases. An overview. Biochimie 1994, 76:234-240. (Review).
53. Cadel S., Foulon T., Viron A., Balogh A., Midol-Monet S., Noel N., Cohen P. Aminopeptidase B from the rat testis is a bifunctional enzyme structurally related to leukotriene-A4 hydrolase. Proc Nat Acad Sci USA 1997, 94:2963-2968.
54. Fontés G., Lajoix A.-D., Bergeron F., Cadel S., Prat A., Foulon T., et al. Miniglucagon-generating endopeptidase, which processes glucagon into miniglucagon, is composed of NRD-convertase and aminopeptidase-B. Endocrinology 2005, 146:702-712.
55. Dalle S., Fontés G., Lajoix A.-D., Le Brigand L., Gross R., Ribes G., Dufour M., Barry L., Le-Nguyen D., Bataille D. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes 2002, 51:406-412.
56. 2+ pathway. J Biol Chem 1999, 274:10869-10876.
57. 2+-channels by a-endosulfine inhibits insulin release. Br J Pharmacol 2002, 135:1810-1818.
58. Yamada M., Inanobe A., Kurachi Y. G protein regulation of potassium ion channels. Pharmacol Rev 1998, 50:723-760. (Review).
59. Dalle S., Longuet C., Costes S., Broca C., Faruque O., Fontés G., Hani E.-H., Bataille D. Glucagon promotes CREB phosphorylation via activation of ERK1/2 (extracellular signal-related kinase 1/2) in MIN6 cell line and isolated islets of Langerhans. J Biol Chem 2004, 279:20345-20355.
60. Power M.L., Schulkin J. Anticipatory physiological regulation in feeding biology: cephalic phase responses 2008, 50:194-206.
61. Fontés G., Imamura T., Ilic C., Puech C., Ktorza A., Bataille D., et al. Miniglucagon: an unexpected insulin's partner in the peripheral effects of the hypoglycemic hormone. Diabetologia 2004, 47(S1):A91.
62. Bataille D., Fontés G., Costes S., Longuet C., Imamura T., Ilic C., et al. The glucagon/miniglucagon interplay: a new level in the metabolic regulation. The VIIth international symposium on VIP, PACAP and related peptides 2005.
63. Bataille D., Fontés G., Costes S., Longuet C., Dalle S. The glucagon-miniglucagon interplay: a new level in the metabolic regulation. Ann NY Acad Sci 2006, 1070:161-166.
64. Bataille D. Proglucagon-derived peptides, metabolic regulation and diabetes: the yin, the yang and beyond. The 13th diabetes and endocrine conference 2007.
65. Proprotein convertases. Methods in molecular biology 2011, vol 768. Humana Press Springer, New York Dordrecht Heidelberg London.
66. Seidah N.G., Sadr M.S., Chrétien M., Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 2013, 288:21473-21481.